Annovis Bio (ANVS) vs Corbus Pharmaceuticals (CRBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Annovis Bio (ANVS) has outperformed Corbus Pharmaceuticals (CRBP) over the past year, losing 81.2% versus a loss of 82.8%. Over five years, CRBP leads with a -92.2% price change compared with -97.2% for ANVS. Annovis Bio is the larger company by market cap ($44.1 million vs $42.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANVS | CRBP |
|---|---|---|
| Share price | $0.7113 | $2.06 |
| Market cap | $44.12M | $42.45M |
| 1-day change | -4.96% | -15.40% |
| YTD return | -79.44% | -74.69% |
| 1-year return | -81.23% | -82.85% |
| 5-year return | -97.24% | -92.23% |
| EPS (TTM) | $-1.55 | $-6.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-28.85M | $-78.54M |
| 52-week high | $5.50 | $12.88 |
| 52-week low | $0.62 | $2.01 |
| Distance from 52-week high | -87.07% | -84.01% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1376.17% | +1551.94% |
| Average volume | 1.82M | 1.11M |
| Shares outstanding | 62.02M | 20.61M |
| Employees | 7 | 36 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Annovis Bio
ANVS stock →Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Corbus Pharmaceuticals
CRBP stock →Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 36 employees
ANVS vs CRBP FAQ
Which is bigger, Annovis Bio or Corbus Pharmaceuticals?
Annovis Bio (ANVS) is larger, with a market capitalization of $44.12M compared with $42.45M for Corbus Pharmaceuticals (CRBP).
Which stock has performed better over the past year, ANVS or CRBP?
ANVS returned -81.23% over the past 12 months, compared with -82.85% for CRBP (price return, excluding dividends). Past performance does not predict future results.
Are Annovis Bio and Corbus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.